
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is introducing a series of new measures to strengthen how key risks associated with antidepressant medicines are communicated to patients, carers and healthcare professionals.
The changes follow an extensive review initiated by the Commission on Human Medicines (CHM), in response to concerns raised by both patients and families about how information on two key areas is communicated in patient information leaflets. These are suicidal thoughts and behaviours, and sexual dysfunction that continues after treatment is stopped.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze